Market Research Report
Hypofibrinogenemia - Epidemiology Forecast - 2030
|Hypofibrinogenemia - Epidemiology Forecast - 2030|
DelveInsight Business Research LLP
Content info: 100 Pages
Delivery time: 2-10 business days
DelveInsight's 'Hypofibrinogenemia- Epidemiology Forecast-2030' report delivers an in-depth understanding of the Hypofibrinogenemia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Hypofibrinogenemia Disease Understanding
Fibrinogen disorders are a set of hereditary or acquired abnormalities generally considered as rare conditions that are majorly classified as either qualitative (type II) or quantitative (type I). Qualitative fibrinogen disorder is a functional disorder that includes dysfibrinogenemia and hypodysfibrinogenemia.
Quantitative fibrinogen disorders, on the other hand, are characterized by the low amount of fibrinogen in the circulation and are further classified as hypofibrinogenemia, characterized by low fibrinogen levels. Generally, normal plasma fibrinogen levels are considered to range from 1.5 to 4.5 g/L; however, in hypofibrinogenaemia, plasma fibrinogen is reduced and characterized by fibrinogen levels lower than 1.5 g/L. In contrast, afibrinogenemia is an autosomal recessive disease, characterized by the complete deficiency of fibrinogen.
It is broadly classified into two types, i.e., Congenital Hypofibrinogenemia and Acquired Hypofibrinogenemia. Congenital fibrinogen disorders are caused by genetic variants occurring within all three fibrinogen genes. However, each gene (FGA, FGB, FGG) differently shows specific variants, wherein "nonsense" variants are mostly found within FGA, while FGG variants are prevalently responsible for missense changes.
In congenital hypofibrinogenemia, genes responsible for producing fibrinogen (a critical blood clotting factor) are unable to make a functional fibrinogen glycoprotein because of an inherited mutation. In contrast, acquired hypofibrinogenemia can result from either severe hepatic disease or disseminated intravascular coagulation (DIC), cardiac surgery, etc.
The Hypofibrinogenemia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Hypofibrinogenemia epidemiology segmented as the Total Cases of Hypofibrinogenemia, Type-Specific Cases of Hypofibrinogenemia (as congenital and acquired), and Acquired Hypofibrinogenemia cases. The report includes the Prevalent scenario of Hypofibrinogenemia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
The epidemiology segment also provides the Hypofibrinogenemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total prevalent population of Hypofibrinogenemia Associated in 7MM countries estimated to be 11,084 cases in 2017.
We interview KOLs, and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
The Hypofibrinogenemia Epidemiology report will allow the user to -
Study Period: 2017-2030
The frequency of congenital fibrinogen disorders in the general population is very low. A North American Registry of Rare Bleeding Disorders has been successful in collecting valuable information on inherited fibrinogen disorders and other rare bleeding disorders. Among all the reported fibrinogen disorders in this registry, afibrinogenemia accounted for 24% of cases, hypofibrinogenemia accounted for 38%, and dysfibrinogenemia accounted for 38%.